WE DEVELOP NATURAL NUTRACEUTICALS

BASED ON STRONG SCIENTIFIC FOUNDATION

WE DEVELOP NATURAL NUTRACEUTICALS

BASED ON STRONG SCIENTIFIC FOUNDATION

ABOUT EPINUTRA

Epinutra develops natural nutraceuticals based on strong scientific foundation. Our affiliate company Thelial Technologies SA made an exciting discovery in their laboratory – a novel mechanism of action for a well characterized food ingredient: Quercetin.

Quercetin acts to reinforce connections between cells. Clinical data show it strengthens esophageal epithelial barrier function, and specifically its resistance to injury upon contact with hydrochloric (gastric) acid (Clinicaltrials.gov NCT02226484, unpublished).

ABOUT EPINUTRA

Epinutra develops natural nutraceuticals based on strong scientific foundation. Our affiliate company Thelial Technologies SA made an exciting discovery in their laboratory – a novel mechanism of action for a well characterized food ingredient: Quercetin.

Quercetin acts to reinforce connections between cells. Clinical data show it strengthens esophageal epithelial barrier function, and specifically its resistance to injury upon contact with hydrochloric (gastric) acid (Clinicaltrials.gov NCT02226484, unpublished).

A naturally-sourced food supplement not a medicine!

With our first product – benesco™ – we are rolling out a food supplement to support esophagus health.

benesco™ has three principal ingredients:

  • Quercetin, which is present in fruits, vegetables and grains, is well-known as a potent antioxidant. Quercetin intake has also been clinically demonstrated to significantly improve esophageal epithelial barrier function in subjects with heartburn due to gastroesophageal reflux disease (GERD) (Clinicaltrials.gov NCT02226484, unpublished). Each benesco™ lozenge contains the quercetin equivalent of three Jonagold apples.
  • Riboflavin (vitamin B2), an essential vitamin that supports the health of your mucosa including the esophagus. Each benesco™ lozenge contains at least 15% of the recommended daily intake of riboflavin.
  • Isomalt, a sweetener derived from sugar beet. benesco™ lozenges are tooth friendly, sugar-free and have only 5 calories each.

Impaired esophagus health is frequently connected to heartburn – a burning sensation in the chest area.

When using a food supplement, please consult your medical practitioner if you are undergoing treatment for a medical condition or if you are pregnant or lactating.

DEVELOPMENT PROCESS

Like so many science-based products, development of benesco™ has literally taken a decade. We tested more than 2000 different molecules to check whether they hit our molecular target of interest. In addition, of course, they had to be safe and part of a healthy diet.

Our findings are further supported by clinical studies. A trial of the principal active ingredient in benesco™ (Quercetin) was conducted in GERD sufferers (Clinicaltrials.gov  NCT02226484). The trial revealed that oral intake of Quercetin significantly strengthened the barrier function of the esophageal epithelium and specifically it improved epithelial resistance to damage upon exposure to hydrochloric (gastric) acid (unpublished).”

Now you may wonder, if these components are in the healthy diet, why take benesco™?

That is because HOW you take benesco™ is important. When you eat food it passes from mouth through the esophagus and into the stomach in 10 seconds or less. This is too quick for an effect. benesco™ is a lozenge. It takes in the range of five minutes to dissolve in the mouth and this period it bathes the esophagus tissue with the active ingredients (check our video for more details). Mint flavouring was preferred by our panel of heartburn sufferers and also helps stimulate saliva production.

This is how the final product came about: minty fresh, sugar free and with natural active ingredients.

OUR TEAM

We are experienced in pharma/food, clinical, scaling, deal making/partnership building and marketing outreach.

Richard Hampson, Ph.D

Co-founder and CEO of Epinutra
  • Ph.D. and Post-Doctoral training in UK and USA.
  • Over 10 years of experience in translational research and commercialization.
  • Research group leader in biotechnology industry.
  • 16 peer-reviewed publications.
  • Co-inventor on two granted patents and published applications.

Luciana Vieira de Moraes, Ph.D

Co-founder and CSO of Epinutra
  • M.Sc., Ph.D. and Post-Doctoral training in Immunology.
  • Over 20 years of experience in research and integrated research management.
  • Extensive experience with preclinical disease models.
  • 23 peer-reviewed publications.

Albert Bredenoord, MD, Ph.D

Scientific advisor and PI of clinical studies
  • Gastroenterologist & Research Professor at Academic Medical Centre (AMC), Amsterdam
  • Has been active for 10 years in the field of benign esophageal diseases.
  • His clinic hosts the largest population of patients with GERD in The Netherlands.
  • Over 100 publications including peer-reviewed articles, book chapters and guidelines.
  • President of a European Esophagus Research Association (EUREOS).

Will van den Tweel, Ph.D

Head of Commercial Development
  • Ph.D in Industrial Microbiology.
  • 30 years of experience in leading international innovation projects, business management and client relationship at DSM.
  • Ex-CEO Reverdia BV.
  • Managed projects at chief responsibility levels with over 50 persons and multiple 10’s of millions of €.

Eva Kloosterhuis

Marketing and communication consultant
  • Bachelor in Food Technology from Wageningen University.
  • Minor in Communication Sciences from the University of Amsterdam.
  • Ongoing Masters in Food Technology, Specialisation in Product Design and Ingredient Functionality
    at Wageningen University.

Anne Niemel

EoE Ambassador
  • Is proactive in finding solutions that help her manage her inflammatory esophagus condition Eosinophilic Esophagitis (EoE).
  • benesco helps her manage EoE and as ambassador she is reaching out to other sufferers.

  • Founder EoEFood, blog author and community manager.

NEWS

EIT Food Accelerator Network (FAN)

June 2021

Very happy to be selected for the EIT FAN 2021. This is a great support for us to achieve our next goals! https://www.eitfan.eu/

EIT Food Venture Summit

November 2020

Delighted to be selected to tell Epinutra’s story in our pitch at @EIT-Food’s virtual #VentureSummit20 (17-18 Nov): https://bit.ly/3ktU2pi

EIT food investment

August 2020

Great news to receive the investment from “EIT food Covid-19 Bridge Fund”. Support to start our clinical trial and accelerate benescoTM roll-out!
https://www.eitfood.eu/covid-19/programmes/bridge-fund

Epinutra in the news

May 2020

Big thanks again to StartLife on taking a look at where we come from and where we want to go.
start-life.nl

Rabobank AIL investment

April 2020

Thanks to the investment by Rabobank, benescoTM launch in the Netherlands can now go ahead!

Epinutra was welcomed by StartLife in Wageningen

Spring 2019

We graduated from the StartLife Accelerate Program and our connection continues – we thank them for their confidence and financial backing (totaling 85k€).
https://start-life.nl/startlife-accelerate/

Epinutra (Thelial BV)

Plus Ultra II
Bronland 10D
6708 WH
Wageningen
The Netherlands

info@epinutra.com